Applied Therapeutics ( (APLT) ) has released its Q2 earnings. Here is a breakdown of the information Applied Therapeutics presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Applied Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformative treatments for rare diseases, with a particular emphasis on central nervous system metabolic disorders. The company is currently advancing its lead drug candidate, govorestat, which targets conditions such as Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD), Classic Galactosemia, and PMM2-CDG.
In its latest earnings report for the second quarter of 2025, Applied Therapeutics highlighted several strategic advancements and financial metrics. The company is preparing for a meeting with the FDA to discuss a potential New Drug Application for govorestat in treating CMT-SORD. Additionally, they have launched a sponsored sorbitol assay to aid in the diagnosis of CMT-SORD, and presented promising clinical trial data at the PNS 2025 Annual Meeting.
Key financial figures reveal a net loss of $21.3 million for the quarter, a significant shift from a net income of $2.9 million in the same period last year. This change is attributed to increased general and administrative expenses, while research and development costs remained relatively stable. The company also reported cash and cash equivalents of $30.4 million, down from $79.4 million at the end of 2024.
Strategically, Applied Therapeutics has entered an out-licensing agreement with Biossil, Inc. for AT-001, and made key leadership promotions to strengthen its clinical and advocacy efforts. The company remains focused on regulatory alignment and advancing its pipeline, with upcoming data presentations and ongoing program reviews.
Looking ahead, Applied Therapeutics is committed to progressing its pipeline and engaging with regulatory bodies to bring its innovative treatments to market. The management’s outlook emphasizes continued dedication to addressing the needs of patients with rare diseases, with a focus on achieving regulatory milestones and expanding their clinical programs.